μ-opioid receptor - Open Access .click

Results 141 to 150 of about 31,247 (253)

Cardiovascular and kidney outcomes of GLP‐1 receptor agonists in adults with obesity: A target trial emulation study

Diabetes, Obesity and Metabolism, Volume 27, Issue 11, Page 6527-6536, November 2025.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) provide cardiovascular and renal benefits in type 2 diabetes, but their real‐world effects in individuals with obesity without diabetes are unclear. This study aimed to evaluate the cardiovascular and kidney outcomes of GLP‐1RAs versus other anti‐obesity medications (AOMs) in adults ...
Huilin Tang +8 more
wiley +1 more source

Intrathecal Delivery of a Mutant μ-Opioid Receptor Activated by Naloxone as a Possible Antinociceptive Paradigm [PDF]

, 2010
Jia‐Horng Kao +5 more
openalex +1 more source

The Therapeutic Potential of Cannabidiol in Skin Conditions

Journal of Cosmetic Dermatology, Volume 24, Issue 11, November 2025.
ABSTRACT Background Dermatological disorders can have a negative impact on quality of life. Cannabidiol (CBD) is a phytocannabinoid found in the Cannabis sativa L. plant. It has multiple molecular targets, many of which are expressed in the skin, and may have therapeutic potential in several skin conditions. Aims This review aims to provide an overview
Maria C. Redmond, David P. Finn
wiley +1 more source

Neuroendocrinology meets addiction: Emerging pharmacotherapies on the horizon

Journal of Internal Medicine, Volume 298, Issue 5, Page 392-423, November 2025.
Abstract Alcohol and other substance use disorders (ASUDs) are prevalent and major contributors to global morbidity and mortality. Their impact extends beyond the individual, imposing significant burdens on families, communities, healthcare systems, and society at large.
Anna Loften +3 more
wiley +1 more source

Compartment-Specific Modulation of GABAergic Synaptic Transmission by μ-Opioid Receptor in the Mouse Striatum with Green Fluorescent Protein-Expressing Dopamine Islands [PDF]